Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01900730 · ClinicalTrials.gov registry record · Phase 2
Study of Valproic Acid (VPA) vs Placebo to Shorten Time of Indwelling Pleural Catheter
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT01900730: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01900730 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01900730, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if receiving valproic acid (VPA) compared to a placebo can reduce the amount of time you will need to have an indwelling pleural catheter compared to the standard of care, which involves using an indwelling pleural catheter alone. VPA is designed to stop cancer cells from dividing and maturing. This may cause the cancer cells to become less malignant and cause less pleural fluid production. A placebo is not a drug. It looks like the study drug but is not designed to treat any disease or illness. It is designed to be compared with a study drug to learn if the study drug has any real effect.
Interventions
- DRUG Placebo
- BEHAVIORAL Questionnaires
- DRUG Valproic Acid (VPA)
- BEHAVIORAL Pill Diary
- BEHAVIORAL Drainage Diary
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2014-07-31 |
| Est. Completion | 2018-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01900730
The ClinicalTrials.gov registry entry for NCT01900730 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01900730 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01900730 about?
NCT01900730 is a clinical study titled "Study of Valproic Acid (VPA) vs Placebo to Shorten Time of Indwelling Pleural Catheter". The goal of this clinical research study is to learn if receiving valproic acid (VPA) compared to a placebo can reduce the amount of time you will need to have an indwelling pleural catheter compared to the standard of care, which involves using an indwelling pleural catheter alone. VPA is designed...
What is the current status of trial NCT01900730?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2014-07-31. Estimated completion is 2018-06-01.
What interventions are being tested in trial NCT01900730?
The interventions under investigation include: Placebo (DRUG), Questionnaires (BEHAVIORAL), Valproic Acid (VPA) (DRUG), Pill Diary (BEHAVIORAL), Drainage Diary (BEHAVIORAL).
Who is sponsoring clinical trial NCT01900730?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.